Development of psoriasis after B cell depletion with rituximab
- PMID: 17665440
- DOI: 10.1002/art.22811
Development of psoriasis after B cell depletion with rituximab
Abstract
The B cell-depleting monoclonal antibody rituximab is a novel therapy for the rheumatic diseases, with an increasing body of evidence regarding its safety and efficacy in an expanding range of indications. However, there is uncertainty over its potential use in, and impact on, autoantibody-negative diseases. We describe 3 patients, with no known risk factor for psoriasis, who developed psoriasis (and 1 who also developed features of psoriatic arthritis) after receiving rituximab for a variety of indications, namely, seropositive and seronegative rheumatoid arthritis and systemic lupus erythematosus. In all cases, the underlying disease responded well to rituximab. The interpretation of this possible side effect of rituximab remains unclear, but a B cell-depleted environment may induce abnormal T cell responses, possibly provoked either by subclinical infection or by the removal of mechanisms whereby B cells regulate T cells. These cases suggest that the pathogenesis of psoriasis may not require normal numbers of B cells and that proposed treatment of psoriasis and psoriatic arthritis with rituximab may result in unpredictable responses.
Similar articles
-
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.Arthritis Rheum. 2006 Feb;54(2):613-20. doi: 10.1002/art.21617. Arthritis Rheum. 2006. PMID: 16447239
-
Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.Rheumatology (Oxford). 2007 Apr;46(4):626-30. doi: 10.1093/rheumatology/kel393. Epub 2006 Dec 19. Rheumatology (Oxford). 2007. PMID: 17189244
-
B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.Pediatrics. 2009 Jan;123(1):e159-63. doi: 10.1542/peds.2008-2361. Epub 2008 Dec 15. Pediatrics. 2009. PMID: 19074962
-
Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.Clin Immunol. 2008 Jun;127(3):280-5. doi: 10.1016/j.clim.2008.01.011. Epub 2008 Mar 11. Clin Immunol. 2008. PMID: 18337174 Review.
-
Rituximab: a B-cell depletion therapy for dermatologic disease.Skin Therapy Lett. 2007 Jul-Aug;12(6):6-9. Skin Therapy Lett. 2007. PMID: 17762903 Review.
Cited by
-
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.BMC Musculoskelet Disord. 2014 Dec 23;15:452. doi: 10.1186/1471-2474-15-452. BMC Musculoskelet Disord. 2014. PMID: 25539805 Free PMC article. Clinical Trial.
-
Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation.J Leukoc Biol. 2013 Oct;94(4):563-73. doi: 10.1189/jlb.1112562. Epub 2013 Apr 29. J Leukoc Biol. 2013. PMID: 23630391 Free PMC article.
-
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.Arthritis Res Ther. 2012;14 Suppl 5(Suppl 5):S1. doi: 10.1186/ar3909. Epub 2012 Nov 8. Arthritis Res Ther. 2012. PMID: 23281743 Free PMC article. Review.
-
Molecular consideration relevant to the mechanism of the comorbidity between psoriasis and systemic lupus erythematosus (Review).Exp Ther Med. 2023 Aug 29;26(4):482. doi: 10.3892/etm.2023.12181. eCollection 2023 Oct. Exp Ther Med. 2023. PMID: 37745036 Free PMC article. Review.
-
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.RMD Open. 2016 Jul 15;2(2):e000239. doi: 10.1136/rmdopen-2015-000239. eCollection 2016. RMD Open. 2016. PMID: 27493788 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical